Physician profile
Steven C Cramer
NPI 1477633568
$112,404.26
in general payments reported to CMS, 2019-2025
13 companies · $14K in 2025
The $14K reported for 2025 was more than what 99% of Neuromuscular Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $128).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $1,530 · 2021: $25K · 2022: $28K · 2023: $24K · 2024: $8,605 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $38K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,798 · Food and Beverage: $406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $37,509.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,797.50 |
| Food and Beverage | $405.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myomo, INC | $46,875.00 | 2021-2025 | |
| Microtransponder, INC. | $19,159.25 | 2022-2025 | |
| Medtronic, INC. | $15,711.62 | 2022-2025 | Pipeline |
| Abbvie INC. | $14,881.12 | 2019-2022 | |
| Biogen, INC. | $7,131.50 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $5,429.75 | 2024 | |
| Medtronic USA, INC. | $1,530.00 | 2020 | |
| Omniscient Neurotechnology America Ltd | $1,250.00 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $150.00 | 2024 | Dysport |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $124.99 | 2021 | |
| Neurocrine Biosciences, INC. | $114.27 | 2019 | |
| Genentech USA, INC. | $46.76 | 2023 | Ocrevus |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Cramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.